Press coverage about Chiasma (NASDAQ:CHMA) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chiasma earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.4078199076914 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of Chiasma (NASDAQ CHMA) traded down $0.09 on Wednesday, reaching $1.65. The company had a trading volume of 161,800 shares, compared to its average volume of 84,274. Chiasma has a 52-week low of $1.25 and a 52-week high of $2.95.

Separately, ValuEngine upgraded Chiasma from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st.

In related news, Director Scott Minick acquired 25,000 shares of the stock in a transaction that occurred on Thursday, September 21st. The stock was purchased at an average cost of $2.37 per share, for a total transaction of $59,250.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 3.80% of the stock is owned by corporate insiders.

WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at

Chiasma Company Profile

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Insider Buying and Selling by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with's FREE daily email newsletter.